Literature DB >> 16613323

Prognostic impact of cholangiocellular and sarcomatous components in combined hepatocellular and cholangiocarcinoma.

Shinichi Aishima1, Yousuke Kuroda, Yoshiki Asayama, Kenichi Taguchi, Yunosuke Nishihara, Akinobu Taketomi, Masazumi Tsuneyoshi.   

Abstract

Combined hepatocellular and cholangiocarcinoma (cHC-CC) is a rare type of liver cancer displaying both hepatocellular and cholangiocellular components. The cholangiocellular carcinoma (CC) in these tumors ranges from focal to prominent. Those cHC-CCs with sarcomatous features are reported to have a poor prognosis. To clarify whether the CC and sarcomatous component affects the prognosis, we classified 40 patients with cHC-CCs into 4 groups according to the presence of a sarcomatous component and the extent of the CC component. Seven (17.5%) tumors showed areas with a sarcomatous component. The remaining tumors were divided into a low-CC group (CC occupying <30% of the tumor, n = 12), a middle-CC group (30%-60%, n = 15), and a high-CC group (>60%, n = 6). Vascular invasion was more frequently present in the high-CC and sarcomatous group than in the other groups (P = .0007). No lymph node metastasis occurred in either the low- or the middle-CC groups, but it was detected in 3 (50%) cases of the high-CC group and in 2 (29%) cases of the sarcomatous group (P < .0001). There was a tendency for tumor size to increase from the low- to the middle- to the high-CC group. The Ki-67 labeling index values for the hepatocellular carcinoma, CC, and sarcomatous components were 11.4% +/- 12.9%, 25.4% +/- 18.3%, and 46.0% +/- 23.6%, respectively. The overall survival of patients in the high-CC and sarcomatous group was significantly poorer than that of patients in the low- and middle-CC groups (P = .0048). By multivariate analysis of overall survival, lymph node metastasis, histological subgroup, and vascular invasion were significant independent prognostic factors. A cHC-CC with a large CC component is as aggressive as cHC-CC with sarcomatous features.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16613323     DOI: 10.1016/j.humpath.2005.08.019

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  13 in total

Review 1.  Biphenotypic (hepatobiliary) primary liver carcinomas: the work in progress.

Authors:  Elizabeth M Brunt; Valerie Paradis; Christine Sempoux; Neil D Theise
Journal:  Hepat Oncol       Date:  2015-07-28

2.  Risk factors for combined hepatocellular-cholangiocarcinoma: a hospital-based case-control study.

Authors:  Yan-Ming Zhou; Xiao-Feng Zhang; Lu-Peng Wu; Cheng-Jun Sui; Jia-Mei Yang
Journal:  World J Gastroenterol       Date:  2014-09-21       Impact factor: 5.742

3.  The Predictive Value of Staging Systems and Inflammation Scores for Patients with Combined Hepatocellular Cholangiocarcinoma After Surgical Resection: a Retrospective Study.

Authors:  Chaobin He; Yize Mao; Jun Wang; Yunda Song; Xin Huang; Xiaojun Lin; Shengping Li
Journal:  J Gastrointest Surg       Date:  2018-04-17       Impact factor: 3.452

Review 4.  Hepatic progenitor cells in human liver tumor development.

Authors:  Louis Libbrecht
Journal:  World J Gastroenterol       Date:  2006-10-21       Impact factor: 5.742

5.  Intrahepatic sarcomatoid cholangiocarcinoma.

Authors:  Shalini Malhotra; Joanna Wood; Talal Mansy; Rajeev Singh; Abed Zaitoun; Srinivasan Madhusudan
Journal:  J Oncol       Date:  2010-04-29       Impact factor: 4.375

6.  Combined hepatocellular and cholangiocarcinoma with sarcomatoid transformation: radiologic-pathologic correlation of a case.

Authors:  Uei Pua; Su-Chong Low; Yu-Meng Tan; Kiat-Hon Lim
Journal:  Hepatol Int       Date:  2009-09-10       Impact factor: 6.047

7.  Genome-wide expression patterns associated with oncogenesis and sarcomatous transdifferentation of cholangiocarcinoma.

Authors:  Min-A Seol; In-Sun Chu; Mi-Jin Lee; Goung-Ran Yu; Xiang-Dan Cui; Baik-Hwan Cho; Eun-Kyung Ahn; Sun-Hee Leem; In-Hee Kim; Dae-Ghon Kim
Journal:  BMC Cancer       Date:  2011-02-19       Impact factor: 4.430

8.  Combined hepatocellular and cholangiocarcinoma originating from the same clone: a pathomolecular evidence-based study.

Authors:  Qian Zhao; Wen-Long Yu; Xin-Yuan Lu; Hui Dong; Yi-Jin Gu; Xia Sheng; Wen-Ming Cong; Meng-Chao Wu
Journal:  Chin J Cancer       Date:  2016-08-24

9.  Immunohistochemical study of hepatocyte, cholangiocyte and stem cell markers of hepatocellular carcinoma: the second report: relationship with tumor size and cell differentiation.

Authors:  Arisa Kumagai; Fukuo Kondo; Keiji Sano; Masafumi Inoue; Takeshi Fujii; Masaji Hashimoto; Masato Watanabe; Yurie Soejima; Tsuyoshi Ishida; Takuo Tokairin; Koji Saito; Yuko Sasajima; Yoshihisa Takahashi; Hiroshi Uozaki; Toshio Fukusato
Journal:  J Hepatobiliary Pancreat Sci       Date:  2016-06-12       Impact factor: 7.027

10.  Intrahepatic Sarcomatous Cholangiocarcinoma: Case Report and Review of the Literature.

Authors:  Thana Boonsinsukh; Vichit Viriyaroj; Thammanij Rookkachart; Therdkiat Trongwongsa
Journal:  Case Rep Surg       Date:  2018-01-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.